Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
| ▸ | GLS | O94925 | 2/20 | 0.37 |
| ▸ | PDCD1 | Q15116 | 7/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 7/20 | 0.36 |
| ▸ | NQO2 | P16083 | 1/20 | 0.36 |
| ▸ | CCKBR | P32239 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.36 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4088107 | 0.89 | PDCD1 (0.41) | PDCD1CD274EPHX1BACE1 | |
| SCHEMBL12053405 | 0.89 | EPHX1 (0.44) | BRD4CREBBPKCNA5GLSPDCD1 | |
| SCHEMBL12053383 | 0.88 | BRD4 (0.43) | BRD4CREBBPKCNA5GLSNQO2 | |
| SCHEMBL12053392 | 0.82 | HDAC1 (0.41) | BRD4CREBBPGLSNQO2TRPV1 | |
| SCHEMBL12053369 | 0.82 | BRD4 (0.47) | BRD4CREBBPGLSPDCD1CD274 | |
| SCHEMBL12053409 | 0.81 | DYRK1A (0.42) | BRD4CREBBPGLSGFERHSD17B10 | |
| SCHEMBL3427833 | 0.80 | HTR7 (0.34) | PDCD1CD274 | |
| SCHEMBL7217916 | 0.79 | HDAC1 (0.49) | BRD4CREBBPGLSCCKBRL3MBTL1 | |
| SCHEMBL9090245 | 0.79 | KCNA5 (0.47) | KCNA5PDCD1CD274L3MBTL1EPHX1 | |
| SCHEMBL12140837 | 0.79 | BRD4 (0.41) | BRD4CREBBPGLSL3MBTL1CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084449-B2 | Dual pharmacophores—PDE4-muscarinic antagonistics | GLAXO GROUP LIMITED (GB) | 2011-12-27 | — | — | US | disclosed |
| US-8071588-B2 | Dual pharmacophores—PDE4-muscarinic antagonistics | GLAXO GROUP LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-8071588-B2 | Dual pharmacophores—PDE4-muscarinic antagonistics | GLAXO GROUP LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-8067408-B2 | Dual pharmacophores—PDE4-muscarinic antagonistics | GLAXO GROUP LIMITED (GB) | 2011-11-29 | — | — | US | disclosed |
| EP-2259681-A1 | DUAL PHARMACOPHORES-PDE4-MUSCARINIC ANTAGONISTICS | Glaxo Group Limited (GB) | 2010-12-15 | — | — | EP | disclosed |
| EP-2249646-A1 | DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS | Glaxo Group Limited (GB) | 2010-11-17 | — | — | EP | disclosed |
| EP-2249830-A1 | DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS | Glaxo Group Limited (GB) | 2010-11-17 | — | — | EP | disclosed |
| US-20090203677-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| WO-2009100169-A1 | DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009100170-A1 | DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009100166-A1 | DUAL PHARMACOPHORES-PDE4-MUSCARINIC ANTAGONISTICS | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | WO | disclosed |
| US-20090203657-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20090197871-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203677-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | PDE4A, PDE4B, PDE1A | BRD4 246/4885CREBBP 3442/4885KCNA5 1769/4885 |
| US-20090203657-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | PDE4A, PDE1A, PDE4B | BRD4 588/4885CREBBP 2752/4885KCNA5 1162/4885 |
| US-20090197871-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | PDE4B, PDE4A, CHRM4 | BRD4 444/4885CREBBP 4115/4885KCNA5 1515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.